Theralase Technologies Inc. (CVE:TLT – Get Free Report) traded down 18.3% during mid-day trading on Thursday . The stock traded as low as C$0.25 and last traded at C$0.25. 199,095 shares traded hands during mid-day trading, an increase of 70% from the average session volume of 117,279 shares. The stock had previously closed at C$0.30.
Theralase Technologies Stock Performance
The stock has a market capitalization of C$57.70 million, a PE ratio of -15.00 and a beta of 1.36. The company has a quick ratio of 3.40, a current ratio of 1.21 and a debt-to-equity ratio of 20.58. The stock has a fifty day moving average of C$0.24 and a 200-day moving average of C$0.20.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- Do ETFs Pay Dividends? What You Need to Know
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- The Most Important Warren Buffett Stock for Investors: His Own
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Does a Stock Split Mean?
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
